Poolbeg Pharma Secures Australian Patent for Lead Cancer Treatment Candidate

Shares in Poolbeg Pharma PLC climbed as much as 10% during Tuesday morning trading following confirmation that the company has secured its first national patent grant for POLB 001, its lead development candidate targeting a severe adverse effect associated with cancer immunotherapy treatments.

IP Australia has granted patent protection encompassing the use of any p38 MAPK inhibitor, including POLB 001, for the prevention of cytokine release syndrome. CRS represents a potentially fatal immune overreaction that can occur in patients undergoing cancer immunotherapy regimens.

Cavendish, acting as corporate broker to the AIM-listed biopharmaceutical group whilst maintaining a buy recommendation with a 19 pence target price, suggested that the patent approval enhances the commercial attractiveness of the asset for potential licensing partners. Tuesday’s share price stood at approximately 4.4 pence.

The broker emphasised that the most significant near-term catalyst remains the TOPICAL clinical trial, which is evaluating POLB 001 as a preventative therapy for CRS in patients with relapsed or refractory multiple myeloma receiving teclistamab, a bispecific antibody developed by Johnson & Johnson. Interim data is anticipated during the second half of 2026.

Cavendish contended that favourable trial results could initiate partnership negotiations and constitute a material value inflexion point for the company. The broker observed that pharmaceutical corporations typically demand demonstrated clinical efficacy as a de-risking prerequisite before entering into licensing arrangements.

The broker also highlighted advantageous sector conditions, noting that major pharmaceutical companies face an estimated 300 billion dollar patent cliff between 2025 and 2030. This dynamic is already accelerating partnering and merger activity across the sector.

Cavendish estimated the total addressable market for POLB 001 in cancer immunotherapy-induced CRS at more than 10 billion dollars, based on independent research commissioned by Poolbeg. The company is concurrently conducting an oral GLP-1 proof of concept trial targeting obesity treatment, with data expected within six to 18 months. Cash reserves are projected to extend into 2027.